Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:administeredBy |
gptkb:cytarabine
anthracycline |
| gptkbp:approvalYear |
2023
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EX18
|
| gptkbp:brand |
Vanflyta
|
| gptkbp:CASNumber |
950769-58-1
|
| gptkbp:contraindication |
history of QT prolongation
concurrent use with strong CYP3A inhibitors |
| gptkbp:developer |
gptkb:Daiichi_Sankyo
|
| gptkbp:hasMolecularFormula |
C29H32N6O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
quizartinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
FLT3 inhibitor
|
| gptkbp:molecularWeight |
528.6 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea diarrhea QT prolongation neutropenia |
| gptkbp:target |
gptkb:FLT3
|
| gptkbp:usedFor |
gptkb:acute_myeloid_leukemia
|
| gptkbp:bfsParent |
gptkb:FLT3_mutation
|
| gptkbp:bfsLayer |
6
|